Bellerophon Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $428.1K

Website

Clinical Trials

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Phase 2

Conditions: Pulmonary Hypertension
Pulmonary Fibrosis

Interventions: Combination Product: Placebo
Combination Product: INOpulse®
Combination Product: Long Term Follow Up

First Posted Date: 2023-02-28

Last Posted Date: 2023-02-28

Lead Sponsor: Bellerophon

Target Recruit Count: 85

Registration Number: NCT05747508

Locations: 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 20 locations

Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Conditions: Pulmonary Fibrosis
Pulmonary Hypertension

First Posted Date: 2022-05-02

Last Posted Date: 2023-02-21

Lead Sponsor: Bellerophon

Registration Number: NCT05356052

Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

Conditions: Coronavirus Infection
COVID-19
Pneumonia, Viral

First Posted Date: 2020-04-24

Last Posted Date: 2023-02-21

Lead Sponsor: Bellerophon

Registration Number: NCT04358588

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

Phase 2

Completed

Conditions: Pulmonary Hypertension
Sarcoidosis, Pulmonary
Pulmonary Fibrosis

Interventions: Combination Product: iNO

First Posted Date: 2018-11-01

Last Posted Date: 2022-08-10

Lead Sponsor: Bellerophon

Target Recruit Count: 17

Registration Number: NCT03727451

Locations: 🇺🇸
Inova Heart and Lung Vascular Institute, Falls Church, Virginia, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 3 locations

Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen

Early Phase 1

Terminated

Conditions: COPD
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension

Interventions: Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr

First Posted Date: 2017-05-01

Last Posted Date: 2023-02-21

Lead Sponsor: Bellerophon

Target Recruit Count: 7

Registration Number: NCT03135860

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Belgium

3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension
Idiopathic Pulmonary Fibrosis

Interventions: Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Drug: inhaled nitric oxide 75 mcg/kg IBW/hr
Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr

First Posted Date: 2014-10-17

Last Posted Date: 2023-02-21

Lead Sponsor: Bellerophon

Target Recruit Count: 8

Registration Number: NCT02267655

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Belgium

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy